Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Assets Average (2020 - 2025)

Apellis Pharmaceuticals has reported Assets Average over the past 6 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Assets Average at $1.1 billion for Q4 2025, up 19.42% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 19.42% YoY), and the annual figure for FY2025 was $980.2 million, up 17.12%.
  • Assets Average for Q4 2025 was $1.1 billion at Apellis Pharmaceuticals, up from $940.1 million in the prior quarter.
  • Over the last five years, Assets Average for APLS hit a ceiling of $1.1 billion in Q2 2022 and a floor of $612.8 million in Q3 2021.
  • Median Assets Average over the past 5 years was $868.9 million (2023), compared with a mean of $871.4 million.
  • Biggest five-year swings in Assets Average: dropped 25.2% in 2021 and later surged 53.02% in 2022.
  • Apellis Pharmaceuticals' Assets Average stood at $703.7 million in 2021, then rose by 16.03% to $816.6 million in 2022, then decreased by 1.6% to $803.5 million in 2023, then rose by 11.2% to $893.5 million in 2024, then increased by 19.42% to $1.1 billion in 2025.
  • The last three reported values for Assets Average were $1.1 billion (Q4 2025), $940.1 million (Q3 2025), and $814.3 million (Q2 2025) per Business Quant data.